L

ast March, Ziopharm Oncology executives said they walked out of an FDA meeting with “positive guidance” on the design of a Phase 3 clinical trial for its experimental IL-12 gene therapy in patients with glioblastoma, the type of aggressive brain cancer afflicting U.S. Sen. John McCain.

Four months later, Ziopharm still hasn’t offered investors any specific details about that “successful” FDA meeting, or a similar meeting held with European regulators.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X